Top Page
Elevate Uranium Ltd
(Sydney:EL8)
Elevate Uranium Ltd (EL8) vs. iShares MSCI Australia ETF (EWA)
Elevate Uranium Ltd Business Overview & Revenue Model
Elevate Uranium Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 768.50K | 768.50K | 182.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 768.50K | 768.50K | -121.67K | -117.68K | -85.52K | -54.29K |
| EBITDA | -19.26M | -11.85M | -10.62M | -8.51M | -5.68M | -2.66M |
| Net Income | -12.32M | -12.32M | -10.75M | -8.63M | -5.73M | -2.60M |
Balance Sheet | ||||||
| Total Assets | 25.46M | 25.46M | 13.26M | 12.54M | 19.33M | 9.96M |
| Cash, Cash Equivalents and Short-Term Investments | 21.71M | 21.71M | 10.83M | 10.06M | 15.81M | 6.66M |
| Total Debt | 432.41K | 432.41K | 74.21K | 146.03K | 177.27K | 99.29K |
| Total Liabilities | 1.57M | 1.57M | 1.48M | 1.02M | 838.59K | 429.54K |
| Stockholders Equity | 23.89M | 23.89M | 11.78M | 11.52M | 18.49M | 9.53M |
Cash Flow | ||||||
| Free Cash Flow | -11.71M | -11.71M | -9.31M | -5.90M | -4.49M | -2.40M |
| Operating Cash Flow | -11.62M | -11.62M | -9.24M | -5.83M | -4.38M | -2.33M |
| Investing Cash Flow | -714.24K | -714.24K | -73.79K | -74.52K | -137.62K | -61.28K |
| Financing Cash Flow | 23.22M | 23.22M | 10.09M | 158.86K | 13.67M | 7.99M |
Elevate Uranium Ltd Technical Analysis
Elevate Uranium Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $15.17B | 7.61 | 4.09% | 5.20% | 3.87% | -62.32% | |
57 Neutral | AU$269.71M | -49.59 | -6.30% | ― | ― | -67.12% | |
47 Neutral | AU$269.03M | -7.40 | -7.01% | ― | -100.00% | 49.49% | |
46 Neutral | AU$123.40M | -7.54 | -69.11% | ― | ― | 1.38% | |
43 Neutral | AU$7.90M | -3.79 | -75.69% | ― | ― | -141.67% | |
41 Neutral | AU$147.00M | -9.04 | -26.26% | ― | ― | -75.25% | |
41 Neutral | AU$15.73M | -34.09 | -0.93% | ― | ― | 8.33% |
Elevate Uranium Ltd Corporate Events
Elevate Uranium Ltd has announced the issuance of new unquoted equity securities, including options and rights, as part of a previously disclosed transaction. This issuance involves 2,865,711 unquoted options exercisable at $0.41, expiring in 2029, and a total of 1,305,699 rights with varying expiration dates. This move is part of the company’s strategic financial maneuvers to support its operations and growth, potentially impacting its market positioning and stakeholder interests.
Elevate Uranium Ltd announced a change in the director’s interest, with Scott Perry acquiring 695,837 service options exercisable at $0.41 per option, expiring on December 1, 2029. This acquisition, following shareholder approval, reflects a strategic move to align the director’s interests with the company’s growth objectives, potentially impacting its market positioning positively.
Elevate Uranium Ltd has announced the grant of unlisted securities following shareholder approval. These include service options and performance rights issued to the company’s directors and managing director, Murray Hill. The securities are structured to vest over several years, aligning with the company’s long-term strategic goals and performance indicators. This move is likely to strengthen the company’s leadership incentives and align their interests with shareholder value, potentially impacting its operational focus and market positioning.
Elevate Uranium Ltd announced the successful passing of all resolutions at its Annual General Meeting held on 27 November 2025. The resolutions included the adoption of the remuneration report, re-election of director Scott Perry, issuance of service options to key personnel, and approval of a 10% placement capacity. These decisions are likely to enhance the company’s governance and operational capacity, potentially impacting its strategic positioning in the uranium market.
Elevate Uranium Ltd has issued an addendum to its Notice of Annual General Meeting, originally dated 6 October 2025. The meeting will proceed as scheduled on 27 November 2025, with the addendum available online for shareholders. This update ensures compliance with regulatory requirements and facilitates shareholder engagement by providing access to important documents digitally.
Elevate Uranium Ltd has issued an addendum to its Notice of General Meeting to update shareholders on recent developments, including a successful capital raise of $25 million through the placement of shares. This capital will be used to accelerate the development of their U-pgrade pilot plant and expand resource drilling, which is expected to enhance the company’s operational capabilities and strengthen its market position in the uranium sector.
Elevate Uranium Ltd has announced the quotation of 71,428,572 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code EL8. This move is part of a previously announced transaction, potentially enhancing the company’s market presence and providing additional capital for its operations.
Elevate Uranium Ltd has successfully raised $25 million through a placement of shares, significantly strengthening its financial position. This funding will be used to accelerate the U-pgrade™ pilot plant program and expand resource drilling in Namibia and Australia, supporting the company’s strategy to enhance its uranium portfolio and pursue strategic growth opportunities.
Elevate Uranium Ltd has requested a trading halt on its securities pending a significant announcement related to a capital raising initiative. This move is intended to provide the company with additional resources to enhance its market position and operational capabilities, with trading expected to resume by 3 November 2025.
Elevate Uranium Ltd has announced a proposed issue of securities, including service options and performance rights, scheduled for November 28, 2025. This move is part of the company’s strategic efforts to enhance its financial position and support its ongoing projects, potentially strengthening its market presence and offering benefits to stakeholders.
Elevate Uranium Ltd has announced its 2025 Annual General Meeting of Shareholders scheduled for 27 November 2025. The meeting will be held in West Perth, and shareholders are encouraged to submit their proxy voting instructions online by 25 November 2025. The company will not be sending physical copies of the meeting notice, which can be accessed online. This move reflects a shift towards digital communication, potentially enhancing shareholder engagement and operational efficiency.
Elevate Uranium Ltd has announced its Annual General Meeting, which will take place on November 27, 2025, at CWA House in West Perth. Shareholders are encouraged to participate in the meeting, either in person or by proxy, to ensure their votes are counted. The company has opted not to send hard copies of the meeting notice, directing shareholders to access it online, reflecting a shift towards digital communication.
Elevate Uranium Ltd announced the issuance of unquoted equity securities, including LTI Performance Rights, LTI Options, and STI Performance Rights, as part of an employee incentive scheme. This move is aimed at aligning employee interests with company goals and potentially enhancing operational performance, which could strengthen its position in the uranium market.
Elevate Uranium Ltd has announced the grant of unlisted securities under its 2023 Employee Incentive Plan. This includes LTI Performance Rights, LTI Options, and STI Performance Rights, all with specific vesting conditions and expiry dates. This move is aimed at incentivizing employees and aligning their interests with the company’s long-term goals, potentially impacting the company’s operational efficiency and market positioning.
Elevate Uranium Ltd has entered into an agreement to sell its Oobagooma Uranium Project in Western Australia to Orpheus Uranium Ltd. This divestment aligns with Elevate’s strategic focus on its core projects, potentially strengthening its position in the uranium market by allowing it to concentrate resources on its key initiatives. The transaction involves cash and equity payments, with Elevate becoming a significant shareholder in Orpheus, indicating a supportive relationship moving forward.
Orpheus Uranium Limited, a company focused on consolidating underexplored uranium assets, has announced its acquisition of the Oobagooma Uranium Project from Elevate Uranium Ltd’s subsidiary. Located in Western Australia’s Canning Basin, the project is notable for its sedimentary-style roll-front mineralization and historical evidence of significant uranium deposits. This acquisition aligns with Orpheus’ strategy to enhance its portfolio of uranium assets across various development stages, leveraging modern exploration techniques to unlock value from known targets.
Cumulus Wealth Pty Ltd has ceased to be a substantial holder in Elevate Uranium Ltd as of September 30, 2025. This change in substantial holding could impact Elevate Uranium’s shareholder dynamics and influence within the company, potentially affecting its strategic decisions and market positioning.
Elevate Uranium Ltd has announced the date for its 2025 Annual General Meeting, scheduled for November 27, 2025, in West Perth. A key agenda item will be the election of directors, with nominations closing on October 7, 2025. This meeting is significant for stakeholders as it will influence the company’s leadership and strategic direction.
Elevate Uranium Ltd has released its corporate governance statement, which adheres to the ASX Corporate Governance Council’s principles and recommendations. The statement outlines the company’s commitment to maintaining robust governance practices, including board oversight and management responsibilities. This announcement reinforces Elevate Uranium’s dedication to transparency and accountability, potentially strengthening its position in the market and providing assurance to stakeholders about its governance standards.
Elevate Uranium Ltd has released its Corporate Governance Statement for the financial year ending June 30, 2025. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s recommendations, detailing the roles and responsibilities of the Board, Chair, and management. The company has implemented a Corporate Governance Plan, which is accessible on their website, to guide their governance duties. This release highlights Elevate Uranium’s commitment to transparency and structured governance, which may enhance stakeholder confidence and potentially improve its industry positioning.